Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma

PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype

(2021) Giorgia Fanelli et al.   PLOS BIOLOGY

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

(2020) Ryosuke Okamura et al.   Journal for ImmunoTherapy of Cancer

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

(2020) Dmitriy Zamarin et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

(2019) Mary L. Disis et al.   JAMA Oncology

FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors

(2019) Leigh Marcus et al.   CLINICAL CANCER RESEARCH

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

(2019) Hideaki Ogiwara et al.   CANCER CELL

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study

(2019) U A Matulonis et al.   ANNALS OF ONCOLOGY

Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities

(2019) Krystal A Orlando et al.   Expert Review of Anticancer Therapy

Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy

(2019) Youngran Park et al.   CLINICAL CANCER RESEARCH

Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications

(2019) Yuxin Lin et al.   Journal of Hematology & Oncology

Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes

(2019) Tuan Zea Tan et al.   EBioMedicine

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

(2018) Stefania Bellone et al.   CLINICAL CANCER RESEARCH

Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer

(2018) Souptik Barua et al.   LUNG CANCER

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

(2018) Jianfeng Shen et al.   NATURE MEDICINE

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

(2018) Katrien Berns et al.   ONCOGENE

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

(2018) Elisa Peranzoni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Repurposing Pan-HDAC Inhibitors for ARID1A -Mutated Ovarian Cancer

(2018) Takeshi Fukumoto et al.   Cell Reports

Improving efficacy of cancer immunotherapy through targeting of macrophages

(2018) Elisa Peranzoni et al.   Human Vaccines & Immunotherapeutics

Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis

(2017) Guangquan Liu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium

(2017) Brian C Willis et al.   MODERN PATHOLOGY

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

(2017) Brooke E. Howitt et al.   OncoImmunology

Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib

(2016) Rowan E. Miller et al.   MOLECULAR CANCER THERAPEUTICS

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

(2016) Chris T. Williamson et al.   Nature Communications

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

(2016) Suet-Yan Kwan et al.   Oncotarget

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

(2015) J. Shen et al.   Cancer Discovery

Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas

(2015) Yuriko Uehara et al.   PLoS One

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition

(2015) Eleftherios P. Samartzis et al.   Oncotarget

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

ARID1B is a specific vulnerability in ARID1A-mutant cancers

(2014) Katherine C Helming et al.   NATURE MEDICINE

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

Erratum: Integrated genomic characterization of endometrial carcinoma

(2013)   NATURE

NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data

(2012) Daryl Waggott et al.   BIOINFORMATICS

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer

(2011) M. S. Anglesio et al.   CLINICAL CANCER RESEARCH

Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas

(2011) David S.P. Tan et al.   CLINICAL CANCER RESEARCH

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types

(2011) Siân Jones et al.   HUMAN MUTATION

ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas

(2010) Kimberly C. Wiegand et al.   NEW ENGLAND JOURNAL OF MEDICINE

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers

(2008) John K. Chan et al.   GYNECOLOGIC ONCOLOGY